Soft Tissue and Bone Sarcoma

Open studyStudy to be openClosed study
1317
Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib
1402
International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours – Euro Ewing 2012
1403
International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
1321
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST).
1202
Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma.
90101
Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE")
62092
A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS) - STRASS
62091
TRUSTS : A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
62063
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
62072
A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.
90061
Multicenter parallel phase II trial of BI 2536 administrered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions (NOCI)
62052
Phase II study of E7389 administered as an IV infusion on day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma
62061
Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
62043
Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma
62024
Intermediate and high risk localized,completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery.
62027
Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22) (q22;q13) translocation resulting in a COL1A1/PDGF- beta fusion protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)
62012
Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma
62022
Phase 2 study of Iressa (ZD 1839) in locally advanced and/or metastatic synovial sarcoma expressing HER1/EGFRI.
62006
Exatecan as second line treatment in advanced adult soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone sarcoma Group. (Study only open for patients with Leiomyosarcoma)
62991
Phase II pilot study of moderate dose radiotherapy for inoperable aggressive fibromatosis
62002
Phase I study to determine the safety of Caelyx (Doxorubicin HCI, pegylated liposomal) in combination with Ifosfamide in previously untreated adult patients with advanced and/or metastatic soft tissues sarcomas.
62005
Phase III randomised, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase (CD117)
62993
A phase II study to evaluate the role of weekly Cisplatin with oral Etoposide in Ewing's sarcoma and primitive neuroectodermal tumour (PNET) with metastasis outside the lung and the pleura.
62001
Dose finding and phase II study of STI 571 in advanced soft tissue sarcoma.
62982
Phase II study on ET-743 in advanced soft tissue sarcomas of the adult.
62972
Phase II Study on Gemcitabine in advanced soft tissue sarcomas of the adult
62971
Randomized phase III trial of two investigational schedules of Ifosfamide versus standard dose Doxorubicin in patients with advanced or metastatic soft tissue sarcoma.
62951
Phase II study on Tomudex in advanced soft tissue sacromas of the adult
62961
Randomized study comparing neoadjuvant chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) combined with regional hyperthermia (RHT) Vs neoadjuvant chemotherapy alone in the treatment of high-risk soft tissue sarcomas in adults. An Intergroup study with the European Society for hyperthermic oncology.
62962
Phase II Study of Caelyx (Doxorubicin HCl, pegylated liposomal) or Doxorubicin in previously untreated adult patients with advanced and/or metastatic soft tissue sarcomas.
62953
Phase II study on HD Ifosfamide in advanced soft tissue sarcomas of the adult
62922
Phase II trial of temozolomide in adult patients with advanced soft tissue sarcoma
62933
Metastasectomy and chemotherapy for lung metastases from soft tissue sarcoma. A randomized phase III study (an Intergroup Study with the Scandinavian Sarcoma Group)
62941
Randomized multicenter phase III trial comparing Docetaxel to Doxorubicin in previously untreated patients with advanced and/or metastatic soft tissue sarcoma
62931
Randomized phase III trial of adjuvant chemotherapy with high-dose doxorubicin, ifosfamide and lenograstim in high grade soft tissue sarcoma.
62932
Phase II study of daily oral vepeside (etoposide VP16-213) as second line treatment in advanced soft tissue sarcomas
62921
A phase II trial with taxotere (RP56976) in advanced soft tissue sarcomas of the adult
62903
Randomized phase III study comparing conventional dose Doxorubicin plus Ifosfamide vs high dose Doxorubicin plus Ifosfamide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of advanced soft tissue sarcomas in adults
04914
Etude de phase II d'un nouveau derive du platine, le lobaplatine (SAR 540), dans les sarcomes avanc‚s des tissus mous de l'adulte
62912
Randomized phase II study comparing two different Ifosfamide dose regimens
62911
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcoma of the adult
62901
Randomized phase II-III study comparing adriamycin versus two schedules of high dose Epirubicin in advanced soft tissue sarcoma
62902
PHASE II STUDY OF DAILY ORAL MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN ADVANCED SOFT TISSUE SARCOMAS OF THE ADULT.
04891
Essais cliniques phase II d'une nouvelle nitrosourée: la Cystémustine dans les poumons, les adénocarcinomes colo-rectaux, les gliomes, les mélanomes, les reins, les sarcomes des parties molles et les tumeurs de la tête et du cou.
62883
Phase II clinical study of the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) with chemotherapy (adriamycin andifosfamide) in the treatment of advanced soft tissue sarcomas in adults
62881
PHASE II STUDY OF ACNU IN METASTATIC SOFT TISSUE SARCOMA
62874
Randomized phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults
62871
Phase II Chemotherapy with m-Azidopyrimethamine in Adults with Metastatic Soft Tissue Sarcoma (Summary Last Modified 05/88)
04861
Etude clinique phase II 4' -0-tetrahydropyranyl adriamycine (THP-ADM-1609 RB)
62863
Phase II study of Mitozolomide in metastatic soft tissue sarcoma
62861
Phase II Chemotherapy with Methylene Dimethane Sulphonate in Patients with Soft Tissue Sarcomas
62851
Phase III trial of first line chemotherapy (adriamycin vs adriamycin + ifosfamide vs cyvadic) in advanced soft tissue sarcoma
62771
Randomized trial for Adjuvant Chemotherapy in soft tissue sarcoma
1447
Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma
1506
A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxi compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based first line chemotherapy for inoperable disease "ANITA"

Back to Site-list